Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Horvath N, Spencer A, Kenealy M, Joshua D, Campbell PJ, Lee JJ, Hou J, Qiu L, Kalff A, Khong T, Londhe A, Siggins S, van Kooten Losio M, Eisbacher M, Prince HM.

Leuk Lymphoma. 2019 Feb 19:1-12. doi: 10.1080/10428194.2019.1579322. [Epub ahead of print]

PMID:
30777794
2.

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF.

Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13.

3.

Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).

Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF.

Leuk Lymphoma. 2017 Feb;58(2):298-307. Epub 2016 Jun 7.

PMID:
27268068
4.

Treatment of chronic myelomonocytic leukemia with azacitidine.

Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M.

Leuk Lymphoma. 2013 Apr;54(4):878-80. doi: 10.3109/10428194.2012.730615. Epub 2012 Oct 5. No abstract available.

PMID:
22988826
5.

When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?

Bird RJ, Kenealy M, Forsyth C, Wellwood J, Leahy MF, Seymour JF, To LB.

Intern Med J. 2012 Apr;42(4):450-5. doi: 10.1111/j.1445-5994.2012.02734.x.

PMID:
22498118
6.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A.

Leukemia. 2012 Jun;26(6):1286-92. doi: 10.1038/leu.2011.391. Epub 2012 Jan 13.

PMID:
22289990
7.

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF.

Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21.

PMID:
20962860
8.

IgA nephropathy associated with cutaneous T cell lymphoma.

Bajel A, Yin Lin M, Hill PA, Goodman D, McCormack C, Foley P, Davison J, Hönemann D, Kenealy M, Lade S, Ryan G, Prince HM.

Leuk Lymphoma. 2009 Dec;50(12):2083-5. doi: 10.3109/10428190903288472. No abstract available.

PMID:
19863174
9.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
10.

Current status of new drugs for the treatment of patients with multiple myeloma.

Kenealy M, Prince HM.

Intern Med J. 2006 Dec;36(12):781-9. Review.

PMID:
17096741
11.

Treatment-related myelodysplasia following fludarabine combination chemotherapy.

Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D.

Haematologica. 2006 Nov;91(11):1546-50.

12.
13.

Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage.

Flouriot G, Griffin C, Kenealy M, Sonntag-Buck V, Gannon F.

Mol Endocrinol. 1998 Dec;12(12):1939-54.

PMID:
9849967
14.

Flecainide acetate for conversion of acute supraventricular tachycardia to sinus rhythm.

Crozier IG, Ikram H, Kenealy M, Levy L.

Am J Cardiol. 1987 Mar 1;59(6):607-9.

PMID:
3103410

Supplemental Content

Loading ...
Support Center